JP2022523972A5 - - Google Patents
Info
- Publication number
- JP2022523972A5 JP2022523972A5 JP2021552609A JP2021552609A JP2022523972A5 JP 2022523972 A5 JP2022523972 A5 JP 2022523972A5 JP 2021552609 A JP2021552609 A JP 2021552609A JP 2021552609 A JP2021552609 A JP 2021552609A JP 2022523972 A5 JP2022523972 A5 JP 2022523972A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- region
- gipr antagonist
- gdf15
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024128733A JP2024156886A (ja) | 2019-03-08 | 2024-08-05 | 増殖分化因子１５併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815866P | 2019-03-08 | 2019-03-08 | |
| US62/815,866 | 2019-03-08 | ||
| PCT/US2020/021314 WO2020185533A1 (en) | 2019-03-08 | 2020-03-06 | Growth differentiation factor 15 combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024128733A Division JP2024156886A (ja) | 2019-03-08 | 2024-08-05 | 増殖分化因子１５併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523972A JP2022523972A (ja) | 2022-04-27 |
| JP2022523972A5 true JP2022523972A5 (https=) | 2023-02-10 |
| JP7536030B2 JP7536030B2 (ja) | 2024-08-19 |
Family
ID=70166143
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552609A Active JP7536030B2 (ja) | 2019-03-08 | 2020-03-06 | 増殖分化因子１５併用療法 |
| JP2024128733A Withdrawn JP2024156886A (ja) | 2019-03-08 | 2024-08-05 | 増殖分化因子１５併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024128733A Withdrawn JP2024156886A (ja) | 2019-03-08 | 2024-08-05 | 増殖分化因子１５併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220152154A1 (https=) |
| EP (1) | EP3934679A1 (https=) |
| JP (2) | JP7536030B2 (https=) |
| AU (1) | AU2020233876B2 (https=) |
| CA (1) | CA3131912A1 (https=) |
| MX (1) | MX2021010737A (https=) |
| WO (1) | WO2020185533A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| UA127495C2 (uk) * | 2015-12-23 | 2023-09-13 | Амджен Інк. | Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить |
| CR20200510A (es) | 2018-04-09 | 2020-11-26 | Amgen Inc | Protreínas de fusión del factor de diferenciación de crecimiento 15 |
| EP4041281B1 (en) | 2019-10-04 | 2025-11-26 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| WO2022103773A1 (en) * | 2020-11-10 | 2022-05-19 | Amgen Inc. | Novel linkers of multispecific antigen binding domains |
| CA3219645A1 (en) * | 2021-05-21 | 2022-11-24 | Yuhan Corporation | Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
| CN120530128A (zh) * | 2022-11-18 | 2025-08-22 | 株式会社柳韩洋行 | 双功能蛋白及其用途 |
| EP4687947A1 (en) | 2023-04-05 | 2026-02-11 | Antag Therapeutics ApS | Gip activity modulators and orthostatic intolerance |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE493998T1 (de) | 1996-08-08 | 2011-01-15 | Amylin Pharmaceuticals Inc | Pharmazeutische zusammensetzung mit einem exendin-4-peptid |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| DE122007000044I2 (de) | 1997-01-07 | 2011-05-05 | Amylin Pharmaceuticals Inc | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
| US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
| ES2293688T5 (es) | 1997-08-08 | 2011-05-04 | Amylin Pharmaceuticals, Inc. | Nuevos compuestos análogos de la exendina. |
| ATE383867T1 (de) | 1997-11-14 | 2008-02-15 | Amylin Pharmaceuticals Inc | Neuartige exendin agonisten |
| US7220721B1 (en) | 1997-11-14 | 2007-05-22 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptides |
| MXPA00004670A (es) | 1997-11-14 | 2003-07-14 | Amylin Pharmaceuticals Inc | Compuestos agonistas de exendina novedosos. |
| US7223725B1 (en) | 1997-11-14 | 2007-05-29 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
| US6703359B1 (en) | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
| EP1054594B1 (en) | 1998-02-13 | 2007-07-04 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and glp-1 |
| ES2278589T3 (es) | 1999-01-14 | 2007-08-16 | Amylin Pharmaceuticals, Inc. | Excendinas destinadas a la inhibicion de glucagon. |
| US20030087820A1 (en) | 1999-01-14 | 2003-05-08 | Young Andrew A. | Novel exendin agonist formulations and methods of administration thereof |
| US6902744B1 (en) | 1999-01-14 | 2005-06-07 | Amylin Pharmaceuticals, Inc. | Exendin agonist formulations and methods of administration thereof |
| US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
| WO2001051078A1 (en) | 2000-01-10 | 2001-07-19 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia |
| DK1641823T3 (da) | 2003-06-12 | 2011-12-12 | Lilly Co Eli | GLP-1-analog fusionsproteiner |
| NZ579621A (en) | 2004-02-11 | 2011-03-31 | Amylin Pharmaceuticals Inc | Hybrid polypeptides with selectable properties |
| CA2862516C (en) * | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| KR101993714B1 (ko) * | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
| EP3701969A1 (en) * | 2014-10-31 | 2020-09-02 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| UA127495C2 (uk) | 2015-12-23 | 2023-09-13 | Амджен Інк. | Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить |
| IL313587A (en) | 2017-01-17 | 2024-08-01 | Amgen Inc | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
| CN111163795A (zh) * | 2017-09-10 | 2020-05-15 | 诺沃挪第克公司 | 用于治疗肥胖症的mic-1和glp-1 |
| CR20200510A (es) * | 2018-04-09 | 2020-11-26 | Amgen Inc | Protreínas de fusión del factor de diferenciación de crecimiento 15 |
| EA202191105A1 (ru) * | 2018-10-22 | 2021-08-03 | Янссен Фармацевтика Нв | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение |
-
2020
- 2020-03-06 WO PCT/US2020/021314 patent/WO2020185533A1/en not_active Ceased
- 2020-03-06 CA CA3131912A patent/CA3131912A1/en active Pending
- 2020-03-06 US US17/436,696 patent/US20220152154A1/en active Pending
- 2020-03-06 AU AU2020233876A patent/AU2020233876B2/en active Active
- 2020-03-06 MX MX2021010737A patent/MX2021010737A/es unknown
- 2020-03-06 JP JP2021552609A patent/JP7536030B2/ja active Active
- 2020-03-06 EP EP20717008.5A patent/EP3934679A1/en active Pending
-
2024
- 2024-08-05 JP JP2024128733A patent/JP2024156886A/ja not_active Withdrawn